-

Eurofins Companies Launch SARS-CoV-2 Variant XBB.1.5 Droplet Digital PCR Assay (ddPCR) for Wastewater Surveillance

Highly sensitive ddPCR analytical tool helps identify rapidly increasing SARS-CoV-2 Variant of Concern, XBB.1.5, in wastewater samples domestically and internationally, expanding the comprehensive SARS-CoV-2 wastewater monitoring platform of the Eurofins network

WEST SACRAMENTO, Calif.--(BUSINESS WIRE)--Eurofins Environment Testing Northern California: Wastewater (EWW) and Eurofins Pandemic Prevention Services (EPPS) today launched a droplet digital PCR (ddPCR) assay for the quantitative analysis of SARS-CoV-2 Variant of Concern (VoC) XBB.1.5 in wastewater.

The XBB.1.5 VoC is differentiated from other SARS-CoV-2 variants currently circulating through identification of a single point mutation. This development furthers the strategic initiative of Eurofins (Paris:ERF) companies to continually monitor novel VoCs showing significant incidence within the U.S. and respond to the rapidly changing landscape of the SARS-CoV-2 pandemic.

Variant XBB.1.5 currently comprises >74% of U.S. SARS-CoV-2 variant distribution and has seen a minimum 10% weekly increase in national prevalence since January 2023. The Eastern U.S. currently has a notably high presence of XBB.1.5, specifically in HHS Region 1 (93%), Region 2 (95%), and Region 3 (85%). The World Health Organization has stated that, along with BQ.1 variants, XBB variants are the most antibody-resistant SARS-CoV-2 variants to date, but do not carry any mutation known to be associated with a potential change in severity.

Empowering community leaders and stakeholders to make evidence-based decisions is central to the Eurofins wastewater surveillance offering - accomplished through robust scientific techniques, complete project development/support, and access to teams of established industry experts in wastewater epidemiology.

Governments, public institutions, and businesses have leveraged wastewater monitoring to protect the populations they serve, Eurofins companies offer technical expertise and support to ensure their strategies and mitigation efforts remain effective.

Key Features

  • Adaptable, scalable wastewater monitoring platform for total SARS-CoV-2 and currently circulating VoCs.
  • Project development and ongoing professional support from the global Eurofins network of wastewater monitoring experts.
  • ddPCR platform provides analytical sensitivity unobtainable through other biological monitoring methods.
  • 72-hour data turnaround time provides a near real-time source of community health information.
  • Immediate availability of EPPS’ ddPCR wastewater monitoring platform and project design services.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With 61,000 staff across a network of 940 laboratories in 59 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contacts

Further information:
Brooke Maharg
Brooke.Maharg@ET.EurofinsUS.com

Eurofins

BOURSE:ERF

Release Versions

Contacts

Further information:
Brooke Maharg
Brooke.Maharg@ET.EurofinsUS.com

More News From Eurofins

Eurofins Scientific SE: Weekly Report on Share Repurchases From 09th March to 13th March 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 09/03/2026 FR0014000MR3 10 000 63.1848 CEUX EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 09/03/2026 FR0014000MR3 30 000 63.1292 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 10/0...

Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples

LYON, France--(BUSINESS WIRE)--Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development and validation of a new liquid chromatography tandem mass spectrometry (LC‑MS/MS) method for the detection and quantification of cereulide toxin in human stool samples. This innovation underlines Eurofins Biomnis’ diagnostic innovation, and its commitment to contributing its expert...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 02nd March to 06th March 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 02/03/2026 FR0014000MR3 30 000 67.7739 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 02/03/2026 FR0014000MR3 10 000 67.7248 CEUX EUROFINS SCIENTIFIC 529900JEHFM...
Back to Newsroom